RT Journal Article
SR Electronic
T1 Ready for a BASE jump? Do not neglect SARS-CoV-2 hospitalization and fatality risks in the middle-aged adult population
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.06.20227025
DO 10.1101/2020.11.06.20227025
A1 Lapidus, Nathanael
A1 Paireau, Juliette
A1 Levy-Bruhl, Daniel
A1 de Lamballerie, Xavier
A1 Severi, Gianluca
A1 Touvier, Mathilde
A1 Zins, Marie
A1 Cauchemez, Simon
A1 Carrat, Fabrice
A1 ,
YR 2020
UL http://medrxiv.org/content/early/2020/11/07/2020.11.06.20227025.abstract
AB Seroprevalence results coupled with surveillance data were used to estimate the SARS-CoV-2 infection hospitalization (IHR) and infection fatality ratios (IFR) in France. IHR and IFR were dramatically high in the very elderly (80-90 years: IHR: 30%, IFR: 11%), but also substantial in middle-aged adults (40-50 years: IHR: 1.2%, IFR: 0.05%).Competing Interest StatementThe authors have declared no competing interest.Clinical Trial#NCT04392388Funding StatementThe SAPRIS-SERO study was supported by Agence Nationale de la Recherche (ANR), #ANR-10-COHO-06, Fondation pour la Recherche Medicale (#20RR052-00), Inserm (Institut National de la Sante et de la Recherche Medicale, #C20-26.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The SAPRIS-SERO study was approved by the Sud-Mediterranee III ethics committee (approval #20.04.22.74247) and electronic informed consent was obtained from all participants for DBS testing.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData are not publicly available. Access to the SI-VIC database must be granted by Sante Publique France and access to serosurvey data must be granted by the SAPRIS-SERO study group.